Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDoris HansenUGUtkarsh GoelAAAimaz Afrough

Discussion

Loading...

Member takes

Overview

Real-world analysis shows bispecific antibody therapy influences progression-free survival in multiple myeloma, indicating the role of several risk factors.

Key Points

  • This analysis aimed to identify high-risk profiles and adverse prognoses in multiple myeloma treated with bispecific antibodies.
  • Analyzed data from 943 multiple myeloma patients treated with bispecific antibodies across 15 centers in the US.
  • Used Kaplan–Meier method to estimate progression-free survival and Cox proportional hazards models to identify predictors.
  • Examined high-risk cytogenetic abnormalities, functional high-risk disease, and extramedullary disease.
  • Median progression-free survival was 7.7 months for the cohort, with several high-risk factors identified.
  • Best overall response rate was 67.1%, with varying outcomes based on prior treatment history and disease characteristics.
  • High-risk cytogenetic abnormalities and elevated ferritin were significant prognostic indicators for poor outcomes.

Cite This Study

Hansen et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daaahttps://doi.org/10.1182/blood-2025-4069
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025
  2. 2Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma2025 · 1 citations
  3. 3Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.2026
  4. 4Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma2025
  5. 5Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025